{"id":"aromatase-inhibition-therapy","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Musculoskeletal pain"},{"rate":"20-40%","effect":"Vaginal dryness"}]},"_chembl":{"chemblId":"CHEMBL488","moleculeType":"Small molecule","molecularWeight":"232.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to a decrease in estrogen levels in the body, which can help slow the growth of hormone receptor-positive breast cancer cells. Aromatase inhibitors are often used in combination with other treatments, such as tamoxifen or chemotherapy, to treat breast cancer.","oneSentence":"Aromatase inhibition therapy works by blocking the enzyme aromatase, which is involved in the production of estrogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:27.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT05030038","phase":"","title":"Oral Aromatase Inhibitors Modify the Gut Microbiome","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-03-29","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT07114601","phase":"PHASE1","title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-06","conditions":"Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm","enrollment":421},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT07222267","phase":"PHASE1","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Breast Cancer, Advanced Solid Tumor","enrollment":86},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT06930859","phase":"","title":"Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-22","conditions":"Breast Cancer","enrollment":2766},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT06843967","phase":"PHASE1, PHASE2","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-19","conditions":"Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma","enrollment":54},{"nctId":"NCT06172088","phase":"NA","title":"Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2023-12-15","conditions":"Breast Cancer Patients Treated With Aromatase Inhibitors","enrollment":54},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT02712723","phase":"PHASE2","title":"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qamar Khan","startDate":"2016-02","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT06650423","phase":"","title":"Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-01-05","conditions":"Early Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":319},{"nctId":"NCT01530373","phase":"PHASE2","title":"Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2012-02","conditions":"Hot Flashes, Breast Cancer","enrollment":110},{"nctId":"NCT05700006","phase":"","title":"Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-07-25","conditions":"Breast Neoplasm Female, Arthralgia, Aging","enrollment":94},{"nctId":"NCT07448558","phase":"NA","title":"Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2026-02-18","conditions":"Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor","enrollment":206},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT06830720","phase":"","title":"A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-20","conditions":"Breast Neoplasms","enrollment":3250},{"nctId":"NCT06123286","phase":"EARLY_PHASE1","title":"Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms","status":"RECRUITING","sponsor":"Philip Chang","startDate":"2025-09-12","conditions":"Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain","enrollment":30},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT07443943","phase":"PHASE2","title":"A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-03-01","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8","enrollment":20},{"nctId":"NCT04498481","phase":"","title":"TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT06401889","phase":"","title":"Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-07-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT02767661","phase":"PHASE3","title":"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-07-19","conditions":"Breast Cancer","enrollment":263},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06507618","phase":"PHASE3","title":"Pre-Operative Window of ET to Inform RT Decisions (POWER II)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-07-19","conditions":"Breast Cancer Female","enrollment":354},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT06557057","phase":"","title":"Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-16","conditions":"HER2-Positive Breast Carcinoma","enrollment":66},{"nctId":"NCT07425990","phase":"NA","title":"FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles","status":"NOT_YET_RECRUITING","sponsor":"University of Novi Sad","startDate":"2026-02","conditions":"Infertility Female, Frozen Embryo Transfer (FET)","enrollment":120},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07394946","phase":"PHASE2","title":"Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Care Hospital & Research Centre Foundation, Lahore","startDate":"2026-06","conditions":"Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer","enrollment":126},{"nctId":"NCT05038735","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Breast Cancer","enrollment":212},{"nctId":"NCT07423611","phase":"PHASE2","title":"ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-10-01","conditions":"Breast Cancer","enrollment":388},{"nctId":"NCT06905301","phase":"","title":"Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-01-23","conditions":"Breast Cancer","enrollment":240},{"nctId":"NCT06440967","phase":"PHASE3","title":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-07-31","conditions":"Hot Flashes","enrollment":540},{"nctId":"NCT03624244","phase":"PHASE2","title":"Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2019-01-23","conditions":"Low Grade Endometrial Stromal Sarcoma","enrollment":40},{"nctId":"NCT07409948","phase":"NA","title":"Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms","status":"NOT_YET_RECRUITING","sponsor":"Addis Ababa University","startDate":"2026-03-15","conditions":"Breast Neoplasms, Musculoskeletal Pain, Arthralgia","enrollment":88},{"nctId":"NCT07405008","phase":"NA","title":"Laser Acupuncture on Carpal Tunnel Syndrome .","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-01","conditions":"Carpal Tunnel Syndrome (CTS) in Breast Cancer Patients","enrollment":54},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT06610565","phase":"NA","title":"Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-09-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05878314","phase":"","title":"Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-04-25","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":504},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT05501886","phase":"PHASE3","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celcuity Inc","startDate":"2022-12-08","conditions":"Breast Cancer","enrollment":701},{"nctId":"NCT07400523","phase":"PHASE3","title":"Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-02-10","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT04923542","phase":"PHASE1, PHASE2","title":"Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-30","conditions":"Brain Metastases, HR+ Metastatic Breast Cancer","enrollment":31},{"nctId":"NCT06831838","phase":"NA","title":"A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-06","conditions":"Breast Cancer","enrollment":115},{"nctId":"NCT06830486","phase":"","title":"Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-02-14","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":"Breast Cancer","enrollment":463},{"nctId":"NCT03712813","phase":"NA","title":"Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2019-10-02","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT02246621","phase":"PHASE3","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-11-06","conditions":"Breast Cancer","enrollment":493},{"nctId":"NCT07379502","phase":"NA","title":"Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate","status":"NOT_YET_RECRUITING","sponsor":"CMH Kharian Medical College","startDate":"2026-03-05","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":60},{"nctId":"NCT03505736","phase":"","title":"Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-21","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":25},{"nctId":"NCT04305496","phase":"PHASE3","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-16","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":818},{"nctId":"NCT06534125","phase":"NA","title":"Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":150},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01984138","phase":"PHASE2","title":"REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Polly A. Niravath, MD","startDate":"2013-09","conditions":"Estrogen Receptor Positive Breast Cancer, Breast Cancer","enrollment":33},{"nctId":"NCT05305924","phase":"PHASE2","title":"Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2021-02-25","conditions":"ER-Positive Breast Cancer, HER2-negative Breast Cancer","enrollment":28},{"nctId":"NCT06311383","phase":"","title":"A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-10-09","conditions":"Breast Cancer","enrollment":2610},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT04568616","phase":"PHASE2","title":"Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2021-08-13","conditions":"Breast Cancer, ER Positive Breast Cancer","enrollment":178},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT07334626","phase":"NA","title":"Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy","status":"RECRUITING","sponsor":"Benha University","startDate":"2026-01-01","conditions":"Breast Cancer, Breast Cancer Survivors, Aromatase Inhibitors","enrollment":60},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT04524000","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-01-08","conditions":"Advanced Breast Cancer","enrollment":24},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT04762979","phase":"PHASE2","title":"Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marina N Sharifi","startDate":"2021-02-12","conditions":"Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer","enrollment":44},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT06028022","phase":"PHASE2","title":"Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-10-18","conditions":"Estrogen Receptor-Positive Breast Carcinoma","enrollment":80},{"nctId":"NCT07307287","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-20","conditions":"SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer","enrollment":30},{"nctId":"NCT06228768","phase":"NA","title":"Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-03-06","conditions":"Postmenopausal, Breast Cancer","enrollment":50},{"nctId":"NCT06728579","phase":"PHASE2","title":"Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-06","conditions":"Breast Cancer Survivor","enrollment":200},{"nctId":"NCT07295457","phase":"NA","title":"Clinical Trial Evaluating the Efficacy and Implementation of an Early Adapted Physical Activity to Prevent and Manage Aromatase Inhibitor-induced Musculoskeletal Pain in Breast Cancer (APIS)","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-30","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT02760030","phase":"PHASE2","title":"Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2017-02-16","conditions":"Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer","enrollment":14},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT02738866","phase":"PHASE2","title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-10-25","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT00984399","phase":"NA","title":"Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-09-22","conditions":"Atrophic Vaginitis, Breast Cancer","enrollment":31},{"nctId":"NCT04943497","phase":"","title":"A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-27","conditions":"Breast Cancer","enrollment":2424},{"nctId":"NCT05315011","phase":"NA","title":"Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia","status":"SUSPENDED","sponsor":"University Hospital, Montpellier","startDate":"2023-05-05","conditions":"Breast Cancer, Aromatase Inhibitors","enrollment":70},{"nctId":"NCT05631795","phase":"PHASE4","title":"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-09","conditions":"Advanced Breast Cancer","enrollment":40},{"nctId":"NCT04597580","phase":"","title":"Personalised Disease Monitoring in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2019-05-08","conditions":"Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer","enrollment":97},{"nctId":"NCT06706414","phase":"PHASE1, PHASE2","title":"NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-03-01","conditions":"Infertility, Male","enrollment":16},{"nctId":"NCT07256769","phase":"","title":"Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2025-09-29","conditions":"Osteoporosis Secondary, Breast Cancer Females","enrollment":134},{"nctId":"NCT07159880","phase":"NA","title":"Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)","status":"RECRUITING","sponsor":"GABRIEL MONTEIRO PINHEIRO","startDate":"2025-09-01","conditions":"PCOS (Polycystic Ovary Syndrome), Infertility, Anovulation","enrollment":20},{"nctId":"NCT04654208","phase":"","title":"Swedish Ibrance Registries Insights (SIRI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-15","conditions":"Malignant Neoplasm of Breast","enrollment":1500},{"nctId":"NCT01992952","phase":"PHASE1, PHASE2","title":"Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Velindre NHS Trust","startDate":"2014-05-07","conditions":"Estrogen Receptor Positive Breast Cancer","enrollment":149},{"nctId":"NCT02630693","phase":"PHASE2","title":"Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-04-08","conditions":"Breast Cancer","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["endocrine therapy","Inhibition therapy, aromatase","Aromatase Inhibition","hormonal therapy","inhibition therapy, aromatase"],"phase":"phase_3","status":"active","brandName":"aromatase inhibition therapy","genericName":"aromatase inhibition therapy","companyName":"University of Nebraska","companyId":"university-of-nebraska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aromatase inhibition therapy works by blocking the enzyme aromatase, which is involved in the production of estrogen. Used for Hormone receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}